Trump echoes Hitler — and MAGA hears it loud and clear
By Heather Digby Parton,
Salon
| 12. 18. 2023
Photo by Gage Skidmore from Peoria, AZ, United States of America, CC BY-SA 2.0, via Wikimedia Commons
Donald Trump believes in eugenics. He really does. Of course, his understanding of it is purely based upon his own belief in his superior genes and good "German blood." He's said it many times in public.
When he said during his first term that he didn't understand why the U.S. allowed people from "shit-hole countries" to emigrate to the U.S. and suggested that we should encourage people from Norway to come instead, it wasn't hard to figure out what he meant by that. His xenophobia never applied to white European immigrants. After all, he married two of them and they are the mothers of four of his five children. His problem is with people of different races.
If someone of a different race expresses devotion to him then of course he likes them. Think of Kim Jong Un, whom he considers to be one of his greatest allies. But it's a very individual thing. For the most part, Trump believes that...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...